All sessions take place in the Auditorium, unless otherwise stated
Training day: Tuesday 17 May

1300 Entrance 3 Foyer: Registration

Queen’s Suite A
Pre-registrar Stream

1330 Welcome
1340 Movement Disorders: Too much or too little: Amit Batla
1420 Neurology as a career: Biba Stanton & Anna Nagy
1440 Developing your CV for a neurology NTN: Laura Midgley

Queen’s Suite B
Registrar Stream

1330 Welcome
1340 Neurotoxicity of new immuno-oncology treatments: Jeremy Rees
1420 Acute neurological emergencies related to inherited metabolic disease in adults: Elaine Murphy

1500 Queen’s Suite Foyer: Coffee Break

1520 Queen’s Suite A
Pre-registrar & Registrar Session
1520 Controversies and challenges in CNS infections: Benedict Michael
1600 Q&A
1700 Close
1930 ABNT dinner, Vivido restaurant
### Wednesday 18 May

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/EVENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900</td>
<td>Opening and Welcome</td>
</tr>
<tr>
<td>0915</td>
<td>Plenary Session 1: Neuropsychiatry</td>
</tr>
<tr>
<td></td>
<td>Tics and Tourette’s: Eileen Joyce, London</td>
</tr>
<tr>
<td></td>
<td>Functional cognitive disorder phenotypes in the differential diagnosis of dementia</td>
</tr>
<tr>
<td></td>
<td>prodromes: Laura McWhirter, Edinburgh</td>
</tr>
<tr>
<td></td>
<td>Positively diagnosing and managing FND: Biba Stanton, London</td>
</tr>
<tr>
<td>1045</td>
<td>Coffee, Exhibition &amp; Posters</td>
</tr>
<tr>
<td></td>
<td>Zogenix Silent Symposium: Navigating rare and complex epilepsies: Deep dive into Dravet syndrome</td>
</tr>
<tr>
<td>1115</td>
<td>Parallel Sessions 1&amp;2</td>
</tr>
</tbody>
</table>

#### Parallel Session 1: Auditorium

**Muscle, nerve and quality**

- IVIg-exposure and thromboembolic event risk: findings from the UK Biobank: Aisling Carr
- Real-world experience of gene therapy with Onasemnogene-Abeparvovec (Zolgensma®) for patients with SMA-type1 in UK: Vasantha Gowda
- Long-term assessment of efgartigimod in patients with generalised myasthenia gravis: ADAPT+ study interim results: Saiju Jacob
- Project NeuroSafe: safety practice in neurology services: Christopher Kipps
- Multi-centre audit of myotonic dystrophy care in UK: is it the time for national recommendations?: Mohit Litesh
- An audit of pregnancy and outcomes in the congenital myasthenic syndromes: Tatiana Rooney
- Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results: Pamela Shaw

#### Parallel Session 2: Hall D

**Neurodegeneration**

- The clinical, imaging, and pathology characteristics of ‘late cases’ of sporadic CJD in the UK: John Centola
- Degraded speech comprehension is a ‘real-world audiogram’ for dementia: Jeremy Johnson
- Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service: Christopher Leahy
- Novel complex motor behaviours in LGI1-autoantibody encephalitis: Sophia Michael
- Using 31-phosphorus magnetic resonance spectroscopy (31P-MRS) to identify Parkinson’s disease subgroups with bioenergetic dysfunction: Thomas Payne
- Risk factors and Parkinson’s disease presentations in primary care in a diverse UK population: Cristina Simonet
- What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?: Cristina Simonet
Wednesday 18 May

1230 Lunch, Exhibition, Posters & Symposia
Queen’s Suite A, Biogen: Personalised treatment approaches to MS DMT management: the world in 2022 and beyond
Queen’s Suite B, Angelini Pharma: Management of drug resistant epilepsy – what’s next?

1400 Gordon Holmes Lecture
Cannabis for Parkinson’s disease; curse or cure: Susan Fox, Western General Hospital, Toronto

1445 Parallel Sessions 3 & 4
Parallel Session 3: Auditorium
Acute/Vascular/Trauma
- Delivering acute neurology care via the Same Day Emergency Care (SDEC) model: Michelle Balaratnam
- Atypical clinical presentations are common in TIA and minor stroke patients with DWI-MRI confirmed ischaemia: Jonathan Best
- Cavernomas- a randomised effectiveness (CARE) trial: treatment with versus without neurosurgery for symptomatic brain cavernoma: Kirsty Harkness
- Circulating Interleukin-6 predicts carotid plaque severity, vulnerability, and progression in the Cardiovascular Health Study: Joseph Kamtchum Tatuene
- Cardiovascular autonomic failure correlates with cutaneous autonomic denervation and patient symptoms in alpha-synucleinopathies: Shiwen Koay
- Autonomic dysfunction after moderate-severe traumatic brain injury: symptom spectrum and clinical testing outcomes: Lucia Li
- Active elite rugby participation predicts alterations in cortical thickness: Thomas Parker

Parallel Session 2: Hall D
Covid
- Acute inflammatory CNS diseases following vaccination against SARS-CoV-2: Anna Francis
- Effectiveness of COVID-19 vaccines in multiple sclerosis patients receiving disease-modifying therapies in England: Afagh Garjani
- COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database: Ryan Keh
- Epilepsy mortality in Wales during COVID-19: William Owen Pickrell
- T-cell response following COVID booster vaccination in seronegative people with multiple sclerosis (MS): Emma Tallantyre
Wednesday 18 May

1600 Coffee, Exhibition & Posters

Zogenix Silent Symposium:
Navigating rare and complex epilepsies: Clinical cases

1630 Plenary Session 2: The neurology of the special senses: The ear and vestibular system

The neurology of the vestibular system - from inner ear to cortex: Barry Seemungal, London
Auditory cognition: Tim Griffiths, Newcastle
Vestibular migraine or PPPD?: Louisa Murdin, London

1800 Studio One: Poster session with discussants 1
Includes trainee and student guided poster tours - see app for details

1900 Drinks reception & posters
Thursday 19 May

0745   ABN Special Interest Groups (SIGs)

Hall Auditorium: SIG 1 - Multiple Sclerosis & Neuroinflammation
Chair: Tarunya Arun and Klaus Schmierer

Hall D: SIG 2 - British Peripheral Nerve Society
Chair: Aisling Carr
There will be a panel of doctors (with a peripheral nerve interest). Each will present a very brief illustrative case. The main body of the session will be questions from the floor. We are keen for attendees to bring along their peripheral nerve questions and dilemmas.

Queen’s Suite A: SIG 3 - Clinical relevance of sustainability
Chair: Sui Wong
Part 1 | Setting the scene: neurologists speaking about the impact of climate change on various neurological conditions:
- Movement disorder: Jan Coebergh
- Headache: Anna Cohen
- Stroke: Beth Davis
Part 2 | Encouraging action: Guest speaker, Dr Kris de Meyer on how to encourage behaviour change in the context of supporting sustainability and neurology
Part 3 | Taking action: Case studies of what has worked so far, and the Sustainability Special Interest Group (SUS SIG) plans for promoting community and professional networks, including talks from Anjum Misbahuddin and Ann Cheesman
Close: transitioning SUS SIG leadership & voting in of new chair

Queen’s Suite B: SIG 4 - Epilepsy
Chair: Lina Nashef & panel with Laura Mantoan (KCL), Lina Nashef (KCL), Nick Moran (East Kent Hospitals) & Khalid Hamandi (Cardiff University)
Laura Mantoan: NORSE-UK: Introduction to framework, research & database
Arjune Sen: NORSE case presentation
Nick Moran: Introducing the NORSE-UK protocol
Richard Selway: Neuromodulation in status epilepticus and potential applications to NORSE
Open forum and panel discussion, then conclusions: Laura Mantoan

0900   Plenary Session 3: TBI
Not waking up after TBI: David Menon, Cambridge
Managing challenging behaviours in TBI: Mike Dilley, London
Predicting outcome in TBI: Good clinical judgment or self-fulfilling nihilism?
Catherine McMahon, Liverpool
### Thursday 19 May

#### 1030
- Coffee, Exhibition, Posters & Roche Silent Symposium:
  - Treatment of individuals with type 2 and 3 Spinal Muscular Atrophy (SMA): Latest findings from the SUNFISH clinical trial

#### 1100
- Studio One: Poster session with discussants 2
  - Includes trainee and student guided poster tours - see app for details

#### 1200
- ABN Medallist Lecture, Hadi Manji:
  - From Eldoret to Harrogate – and a life in-between
  - Citation: Tom Warner

#### 1245
- Lunch, Exhibition, Posters & Symposia
  - Queen’s Suite A, Teva UK: Monoclonals for migraine: are they meeting expectations?
  - Queen’s Suite B, Novartis: Does treating early improve patient outcomes in RRMS and SPMS?

#### 1415
- AGM

#### 1500
- ABN Equality, Diversity & Inclusion committee: Survey results & discussion
  - Chair: Richard Davenport
  - Arani Nitkunan, London

#### 1545
- Coffee, Exhibition, Posters & Roche Silent Symposium:
  - Treatment of individuals with type 2 and 3 Spinal Muscular Atrophy (SMA): Latest findings from the SUNFISH clinical trial

#### 1615
- Plenary Session 4: Future therapeutics/future diagnostics and therapeutics
  - On trial: Breaking the impasse in neurodegeneration: Nigel Leigh, Brighton
  - Neurological complications of checkpoint inhibitors: Aisling Carr, London

#### 1715
- Regional Opportunities Forum
  - Following the success at the Edinburgh ABN 2019 conference, the Research Opportunities Forum is a 45 min session to pitch the professional and personal attractions of working in neurology centre regions. This includes research opportunities for both early and established career academics, leading disease-specific models of care and trials, alongside wider attractions of the area.
  - This year areas will be represented by Pamela Shaw from Sheffield, Rhys Thomas from Newcastle, Anthony Marson from Liverpool, Helen Ford from Leeds and Monty Silverdale from Manchester. The session is especially aimed at those looking for research opportunities, but also consultant colleagues interested in what’s going on elsewhere and whether the grass looks greener.

#### 1800
- Close

#### 1830
- Gala Dinner drinks reception, Royal Hall
Friday 20 May

0700 Funrun / yoga
0745 ABN Special Interest Groups (SIGs)

Auditorium: SIG 5 - Autonomic
Chairs: Valeria Iodice, Gordon Ingle & Jalesh Panicker

Part 1 | Small fibre involvement in autonomic disorders. This session will include:
• A general introduction to the subject (clinical and research)
• Discuss the clinical relevance of assessing small fibre function and how this helps defining diagnosis and monitoring progression
• Techniques for assessment
• A selection of cases for discussion.

Part 2 | Possible ABN guidelines for the management of neurogenic urogenital dysfunction for the practicing neurologist

Hall D: SIG 6 - Movement Disorders
Chair: Mark Edwards

Queen’s Suite A: SIG 7 - Acute Neurology, sharing experiences in the UK
Chair: Holger Allroggen
Arani Nitkunan: Providing an acute neurology service at a district general hospital in Croydon
Martin Sadler: Acute Neurology - the Plymouth experience
Barry Seemungal: Re-organising acute neurology care in North West London - a recent experience
Robert Simister: Lessons from the first six months of a pilot neurology - SDEC service in a central London hospital
Q & A panel discussion

Queen’s Suite B: SIG 8 - Neuro-Ophthalmology
Chairs: Gordon Plant and Sui Wong
Interactive case presentation: A neuro-ophthalmic update on low and high intracranial pressure syndromes (see UKNOS.com for programme)

0900 Case presentation competition & top posters
• A novel neurodegenerative disease with multi-system features: Leah Holm-Mercer
• West is best - a strongman with numb feet: Marc Edwards
• An astra-nomical headache: Trisha Mukherjee
• Changing phenotypes, a spectrum over 10 years: Aye Moe
• Back to basics: Nicholas Keyi Sim
• Cryptic confusion: Frederick Vonberg

1015 Practical Neurology Lecture
Are we (just) our brains? Raymond Tallis

1100 Coffee, Exhibition & Janssen Silent Symposium

Presentation on clinical trial data of ponesimod
Friday 20 May

1130 Parallel Sessions 5 & 6
Parallel Session 5: MS and neuroinflammation
  - Extended interval dosing of ocrelizumab reduces risk of developing hypogammaglobulinaemia: Christopher Allen
  - Longitudinal clinical study of patients with white matter iron rims lesions in multiple sclerosis: Amjad Altokhis
  - Clinical relevance and utility of GAD65 antibodies in neurological disease: an eight year cohort study: Rachel Brown
  - Impact of rituximab regime on time to relapse in aquaporin-4 antibody positive neuromyelitis spectrum disorder: Moneeb Nasir
  - Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS): Ruth Dobson
  - Single-cell profiling of MS CSF B cells highlights roles for TNFα and mTORC1 signalling: Benjamin Jacobs
  - The clinical and immunological effects of a distinct HLA in patients with CASPR2-antibodies: James Varley

Parallel Session 6: Hall D
Epilepsy and headache
  - Network changes predicting language decline following anterior temporal lobe resection: Lawrence Binding
  - Long term outcomes of deep brain stimulation for treatment refractory chronic cluster headache and SUNHA: Sanjay Cheema
  - Attenuated heart-brain integration predicts functional non-epileptic seizures: Samia Elkommos
  - The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths: Gashirai Mbizvo
  - Associations between antiepileptic use and hypogammaglobulinaemia: findings from a population-based case-control study using data linkage: Sarah Perrott
  - Idiopathic intracranial hypertension: evaluation of births and fertility through the hospital episode statistic dataset 2002-2020: Mark Thaller
  - Future approaches to seizure source localisation using optically pumped magnetencephalography and electrical impedance tomography: Umesh Vivekananda

1245 Lunch, Exhibition, Posters & Symposia
Queen’s Suite A, Argenx: Myasthenia Gravis: optimal treatment for today and what the future may hold
Queen’s Suite B, AbbVie: The role of agility & adaptability in the treatment of neurological conditions

1415 Plenary Session 5: Updates for the general neurologist
The use and abuse of genetic testing: Helen Grote, London
Challenges in AIE: Sarosh Irani, Oxford
Hereditary muscle disorders for the general neurologist: James Lilleker, Manchester

1545 CPC
Discussant: Rhys Davies, Liverpool

1630 Prize presentations & close